Early response predictive of future stable MR4.5 in imatinib-treated patients with CML

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.